Format

Send to

Choose Destination
Diabetologia. 2020 Jan 23. doi: 10.1007/s00125-020-05085-9. [Epub ahead of print]

Diabetic neuropathy: what does the future hold?

Author information

1
Department of Neurology, University of Michigan, 109 Zina Pitcher Place, 4021 BSRB, Ann Arbor, MI, 48104, USA.
2
Veterans Affairs Healthcare System, Ann Arbor, MI, USA.
3
Department of Neurology, University of Colorado, Denver, CO, USA.
4
Department of Neurology, University of Michigan, 109 Zina Pitcher Place, 4021 BSRB, Ann Arbor, MI, 48104, USA. efeldman@med.umich.edu.

Abstract

Frustratingly, disease-modifying treatments for diabetic neuropathy remain elusive. Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but not in those with type 2 diabetes, which constitute the vast majority of patients. Encouragingly, recent evidence points to new metabolic risk factors and mechanisms, and thus also at novel disease-modifying strategies, which are desperately needed. Obesity has emerged as the second most important metabolic risk factor for neuropathy (diabetes being the first) from consensus findings of seven observational studies in populations across the world. Moreover, dyslipidaemia and altered sphingolipid metabolism are emergent novel mechanisms of nerve injury that may lead to new targeted therapies. Clinical history and examination remain critical components of an accurate diagnosis of neuropathy. However, skin biopsies and corneal confocal microscopy are promising newer tests that have been used as outcome measures in research studies but have not yet demonstrated clear clinical utility. Given the emergence of obesity as a neuropathy risk factor, exercise and weight loss are potential interventions to treat and/or prevent neuropathy, although evidence supporting exercise currently outweighs data supporting weight loss. Furthermore, a consensus has emerged advocating tricyclic antidepressants, serotonin-noradrenaline (norepinephrine) reuptake inhibitors and gabapentinoids for treating neuropathic pain. Out-of-pocket costs should be considered when prescribing these medications since their efficacy and tolerability are similar. Finally, the downsides of opioid treatment for chronic, non-cancer pain are becoming increasingly evident. Despite these data, current clinical practice frequently initiates and continues opioid prescriptions for patients with neuropathic pain before prescribing guideline-recommended treatments.

KEYWORDS:

Diabetes; Dyslipidaemia; Exercise; Neuropathy; Obesity; Opioids; Pain; Skin biopsy; Sphingolipids; Weight loss

PMID:
31974731
DOI:
10.1007/s00125-020-05085-9

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center